Nitric oxide activation of poly(ADP-ribose) synthetase in neurotoxicity

Science

Volumn 263, Issue 5147, 1994, Pages 687-689

  Zhang, Jie ^a   Dawson, Valina L ^b   Dawson, Ted M ^a   Snyder, Solomon H ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b NIDA Addiction Research Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BENZAMIDE; NITRIC OXIDE; SYNTHETASE;

ADENOSINE DIPHOSPHATE RIBOSYLATION; ANIMAL TISSUE; ARTICLE; BRAIN; CONTROLLED STUDY; ENZYME ACTIVITY; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALIA;

EID: 0028294246     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.8080500     Document Type: Article

References (37)

1. C. F. Nathan and J. B. Hibbs Jr., Curr. Opin. Immunol. 3, 65 (1991).
2. S. Moncada, R. M. J. Palmer, E. A. Higgs, Pharmacol. Rev. 43, 109 (1991); L. J. Ignarro, Annu. Rev. Pharmacol. Toxicol. 30, 535 (1990).
3. S. Moncada, R. M. J. Palmer, E. A. Higgs, Pharmacol. Rev. 43, 109 (1991); L. J. Ignarro, Annu. Rev. Pharmacol. Toxicol. 30, 535 (1990).
4. D. S. Bredt and S. H. Snyder, Neuron 8, 3 (1992).
5. V. L. Dawson et al., Proc. Natl. Acad. Sci. U.S.A. 88, 6368 (1991); V. L. Dawson et al., J. Neurosci. 13, 2651 (1993).
6. V. L. Dawson et al., Proc. Natl. Acad. Sci. U.S.A. 88, 6368 (1991); V. L. Dawson et al., J. Neurosci. 13, 2651 (1993).
7. T. M. Dawson and S. H. Snyder, J. Neurosci., in press.
8. J. P. Nowicki, D. Duval, H. Poignet, B. Scatton, Eur. J. Pharmacol. 204, 339 (1991).
9. 32P]NAD is a covalent bond between NAD and a thiol residue in GAPDH [L. J. McDonald and J. Moss, Proc. Natl. Acad. Sci. U.S.A. 90, 6238 (1993)].
10. 32P]NAD is a covalent bond between NAD and a thiol residue in GAPDH [L. J. McDonald and J. Moss, Proc. Natl. Acad. Sci. U.S.A. 90, 6238 (1993)].
11. 32P]NAD is a covalent bond between NAD and a thiol residue in GAPDH [L. J. McDonald and J. Moss, Proc. Natl. Acad. Sci. U.S.A. 90, 6238 (1993)].
12. 32P]NAD is a covalent bond between NAD and a thiol residue in GAPDH [L. J. McDonald and J. Moss, Proc. Natl. Acad. Sci. U.S.A. 90, 6238 (1993)].
13. 32P]NAD is a covalent bond between NAD and a thiol residue in GAPDH [L. J. McDonald and J. Moss, Proc. Natl. Acad. Sci. U.S.A. 90, 6238 (1993)].
14. J.-C. Drapier and J. B. Hibbs Jr., J. Clin. Invest. 78, 790 (1986).
15. M. Lepoivre et al., J. Biol. Chem. 265, 14143 (1990); N. S. Kwon et al., J. Exp. Med. 174, 761 (1991).
16. M. Lepoivre et al., J. Biol. Chem. 265, 14143 (1990); N. S. Kwon et al., J. Exp. Med. 174, 761 (1991).
17. D. A. Wink et al., Science 254, 1001 (1991).
18. T. Nguyen et al., Proc. Natl. Acad. Sci. U.S.A. 89, 3030 (1992).
19. G. de Murcia, J. Menissier-de Murcia, V. Schreiber, Bioessays 13, 455 (1991); J. E. Cleaver and W. F. Morgan, Mutat. Res. 257, 1 (1991).
20. G. de Murcia, J. Menissier-de Murcia, V. Schreiber, Bioessays 13, 455 (1991); J. E. Cleaver and W. F. Morgan, Mutat. Res. 257, 1 (1991).
21. J. C. Gaal et al., Trends Biol. Sci. 12, 129 (1987); N. A. Berger, Radiat. Res. 101, 4 (1985).
22. J. C. Gaal et al., Trends Biol. Sci. 12, 129 (1987); N. A. Berger, Radiat. Res. 101, 4 (1985).
23. 14C]NAD.
24. 18 column. Benzamide treated with SNP was 100% recovered at the same elution time point with the same ultraviolet spectrum as that of untreated benzamide. When SNP-treated benzamide and benzamide were mixed and analyzed, only one peak was observed. Benzamide, at 0.03, 0.1, 0.3, and 1 mM, did not compete with cytochrome c for being reduced by superoxide generated from xanthine and xanthine oxidase.
25. 50 for benzamide in inhibiting PARS in vitro is 22 μM [M Banasik, H. Komura, M. Shimoyama, K. Ueda, J. Biol. Chem. 267, 1569 (1992)]. In intact cells, a higher value would be anticipated because benzamide would be competing with millimolar endogenous concentrations of NAD [R. McNerney et al., Biochim. Biophys. Acta 1009, 185 (1989)].
26. 50 for benzamide in inhibiting PARS in vitro is 22 μM [M Banasik, H. Komura, M. Shimoyama, K. Ueda, J. Biol. Chem. 267, 1569 (1992)]. In intact cells, a higher value would be anticipated because benzamide would be competing with millimolar endogenous concentrations of NAD [R. McNerney et al., Biochim. Biophys. Acta 1009, 185 (1989)].
27. R. D. Randall and S. A. Thayer, J. Neurosci. 12, 1882 (1992); D. W. Choi, Neuron 1, 623 (1988); J. Neurosci. 10, 2493 (1990).
28. R. D. Randall and S. A. Thayer, J. Neurosci. 12, 1882 (1992); D. W. Choi, Neuron 1, 623 (1988); J. Neurosci. 10, 2493 (1990).
29. R. D. Randall and S. A. Thayer, J. Neurosci. 12, 1882 (1992); D. W. Choi, Neuron 1, 623 (1988); J. Neurosci. 10, 2493 (1990).
30. Nitrite formation in a human kidney 293 cell line stably transfected with the cDNA for brain NOS was measured in response to A23187 (10 μM) as described [D. S. Bredt, C. D. Ferris, S. H. Snyder, J. Biol. Chem. 267, 10976 (1992)]. A23187 (10 μM) elicited the formation of 17.1 ± 2.1 μM nitrite in 2 hours. Benzamide (100 μM) did not prevent the formation of nitrite (15.9 ± 3.8 μM nitrite), and 100 μM nitroarginine diminished nitrite formation to 3.9 ± 1.6 μM nitrite (mean ± SEM, n = 3).
31. See, for example, O. H. Lowry et al., J. Biol. Chem. 239, 18 (1964); D. Uematsu et al., Brain Res. 482, 129 (1989); K. M. Raley and P. Lipton, Neurosci. Lett. 110, 118 (1990).
32. See, for example, O. H. Lowry et al., J. Biol. Chem. 239, 18 (1964); D. Uematsu et al., Brain Res. 482, 129 (1989); K. M. Raley and P. Lipton, Neurosci. Lett. 110, 118 (1990).
33. See, for example, O. H. Lowry et al., J. Biol. Chem. 239, 18 (1964); D. Uematsu et al., Brain Res. 482, 129 (1989); K. M. Raley and P. Lipton, Neurosci. Lett. 110, 118 (1990).
34. B. Meldrum and J. Garthwaite, Trends Pharmacol. Sci. 11, 379 (1990).
35. B. Kallman et al., Life Sci. 51, 671 (1992).
36. Primary neuronal cultures from cortex were prepared from fetal Sprague-Dawley rats, gestation day 13 to 14. Mature neurons (more than 21 days in culture) were used in all experiments. We determined neurotoxicity by exposing the neurons to the various test solutions as described (4). NMDA, SNP, or SNAP were applied to the cells for 5 min, then the cells were washed and replaced with minimum essential medium and 21 mM glucose overnight in the incubator. After 20 to 24 hours of exposure to test solutions, the neurons were exposed to 0.4% Trypan blue in control salt solution to stain the residue of nonviable cells and to assess toxicity. Viable and nonviable cells were counted. At least two separate experiments using four separate wells were done for each data point shown. Significant overall values were obtained with a one-way, between-groups analysis of variance. Specific comparisons on all possible pair combinations were made with the Student's f test for independent means.
37. We thank S. Pou (Department of Pharmacology and Toxicology, University of Maryland School of Pharmacy) for NO, R. Henning (Leiter Der Pharma-Forschung, Cassella A.G., Frankfurt, Germany) for providing SIN-1, H. Zhou for providing purified pTrcA, and N. Bruce for manuscript preparation. Supported by USPHS grants DA-00266, contract DA-271-90-7408, Research Scientist Award DA-00074 (S.H.S.), a grant from Asahi Chemical Company, and a grant of the W. M. Keck Foundation. T.M.D. was supported by USPHS Clinical Investigator Development Award NS-01578 and a grant from the American Academy of Neurology. V.L.D. was supported by an Intramural Research Training Award from NIH.